Compounded tirzepatide isn’t FDA-approved. This means there’s no guarantee it’s safe or effective. If you’re considering it, go to a safe source. Just because you can buy tirzepatide ...

As the New Year begins, the U.K.’s Medicines and Healthcare Products Regulatory Agency (MHRA) is urging the public to avoid ...

Eli Lilly and Novo Nordisk have been competing in the obesity market for the past year, making it an opportune time to review the benefits of the two most prominent obesity medications.

Eli Lilly (LLY) stock fell as its obesity therapy tirzepatide missed forecasts, amid focus on compounded weight loss ...

Our analyst team just revealed what they believe are the 10 best stocks to buy right now. See the 10 stocks » The supply problem has been one of the biggest risks for Lilly. With the tirzepatide ...

Eli Lilly's diverse product portfolio and promising pipeline, including Tirzepatide, Orforglipron, and Retatrutide, support a "buy" rating for long-term investors despite current valuation metrics.